Sanofi Licenses Seawolf DNA Delivery Programs

Company Seawolf; Sanofi Event Type Research and exclusive-license collaboration Modality Redosable LNP-DNA delivery Asset TRIDENT platform (undisclosed targets) Target Undisclosed Disease Area Bleeding disorders and other undisclosed indications Summary Seawolf disclosed a multi-target Sanofi research and exclusive-license collaboration covering bleeding disorders and other undisclosed indications.…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *